Loading...
Market
What type of candidate from the Flagship Pioneering and GSK collaboration will enter clinical trials first by December 31, 2024?
2
Resolution / Starting Odds
Respiratory drug • 25%
Immunology drug • 25%
Vaccine • 25%
Other • 25%
Official announcements from Flagship Pioneering or GSK, clinical trial registries
Story
Flagship Pioneering and GSK Announce Multibillion-Dollar Collaboration to Develop 10 New Drugs and Vaccines
Jul 29, 2024, 11:12 AM
Flagship Pioneering and GSK have announced a strategic collaboration to discover and develop a portfolio of novel medicines and vaccines, focusing initially on respiratory and immunology. The partnership involves a multibillion-dollar deal to develop up to 10 new drugs. GSK has committed an initial investment of $150 million, with potential additional funding of up to $720 million in upfront, development, and sales milestones, along with tiered royalties for each acquired program. This collaboration aims to leverage GSK’s disease expertise and Flagship’s innovative approaches, including the use of generative artificial intelligence (AI) and high throughput chemical protein synthesis.
View original story
Similar markets
Positive • 25%
Negative • 25%
Neutral • 25%
Not Reported • 25%
Cancer • 25%
Infectious Diseases • 25%
Autoimmune Diseases • 25%
Other • 25%
Cancer • 25%
Cardiovascular disease • 25%
Neurological disorder • 25%
Other • 25%
Significant efficacy • 25%
Moderate efficacy • 25%
No efficacy • 25%
Inconclusive results • 25%
ARO-DUX4 • 25%
ARO-MMP7 • 25%
Other program • 25%
No program reaches Phase 2 • 25%
Cancer • 25%
Autoimmune disorders • 25%
Infectious diseases • 25%
Other • 25%